GILD/ABBV/ENTA/BMY/MRK—Prior authorization is a given for reimbursement of all-oral HCV regimens by US third-party payers; even GILD’s COO, John Milligan has conceded this. The question is how strict the payers’ rules will be with respect to treating the sickest patients first (#msg-101786038).
Market Data 
Markets 
AI
